Research programme: complement-mediated disorders therapeutics - Alexion Pharmaceuticals

Drug Profile

Research programme: complement-mediated disorders therapeutics - Alexion Pharmaceuticals

Alternative Names: mAb 171; TA 106; TT 31; TT 32; TT 33

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taligen Therapeutics
  • Developer Alexion Pharmaceuticals
  • Class Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Complement system protein inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Asthma; Transplant rejection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intraocular, Injection)
  • 01 Feb 2011 Taligen Therapeutics has been acquired and merged into Alexion Pharmaceuticals
  • 07 Oct 2008 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top